Elicera Therapeutics AB (SE:ELIC)

:ELIC

ELIC

Elicera Therapeutics AB

RESEARCH TOOLSreports

Want to see SE:ELIC full AI Analyst Report?

Elicera Therapeutics AB (ELIC) Price & Analysis

3 Followers

ELIC Stock Chart & Stats

kr5.35

kr0.03(1.27%)

At close: Mar 06 4:00 PM EST

kr5.35

kr0.03(1.27%)

Day’s Range― - ―

52-Week Rangekr2.95 - kr8.21

Previous CloseN/A

Volume204.65K

Average Volume (3M)134.24K

Market Cap

kr214.77M

Enterprise Valuekr129.08M

Total Cash (Recent Filing)kr24.85M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.07

Next Earnings

Aug 21, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.41

Shares Outstanding72,803,314

10 Day Avg. Volume92,396

30 Day Avg. Volume134,243

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)10.19

Price to Sales (P/S)0.00

P/FCF Ratio-11.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.49

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Zero Debt / Low LeverageA debt-free capital structure materially reduces solvency risk and interest obligations, preserving flexibility to fund R&D through equity or partnerships. For an R&D-stage biotech this durable conservatism lengthens runway options and reduces fixed financial burden over months.

Immuno-oncology Platform FocusA platform approach across CAR T, oncolytic viruses and the iTANK technology provides multiple development pathways and 'shots on goal.' Structurally attractive immuno-oncology demand and platform IP can enable durable partnerships, licensing or asset monetization opportunities.

Strong Gross Margins When Revenue ExistedHistory of high gross profit on periods with revenue indicates potential for scalable, high-margin commercialization if clinical programs translate to products. Durable margin potential means future revenues could flow to the bottom line faster once fixed R&D overheads are controlled.

Bears Say

Persistent Operating LossesSustained operating losses reflect an ongoing need for external funding and erode retained capital. Over a multi-month horizon this creates dilution risk, constrains strategic choices, and forces management to prioritize financing over long-term value creation unless a clear commercialization path emerges.

Cash Burn / Negative Cash FlowPersistent negative operating and free cash flow is typical for development-stage biotech but is a durable weakness: it necessitates recurring financing, increases execution risk for trials, and limits ability to self-fund operations or scale programs without dilutive equity or partner deals.

Revenue Volatility & 2025 Revenue = 0Sharp revenue volatility and a drop to zero in 2025 undermines commercial visibility and suggests reliance on one-off or unstable income sources. Over months this weakens forecasting, hampers reinvestment planning, and heightens dependency on financing until sustainable revenue streams are established.

ELIC FAQ

What was Elicera Therapeutics AB’s price range in the past 12 months?

Elicera Therapeutics AB lowest stock price was kr2.94 and its highest was kr8.21 in the past 12 months.

What is Elicera Therapeutics AB’s market cap?

Elicera Therapeutics AB’s market cap is kr214.77M.

When is Elicera Therapeutics AB’s upcoming earnings report date?

Elicera Therapeutics AB’s upcoming earnings report date is Aug 21, 2026 which is in 92 days.

How were Elicera Therapeutics AB’s earnings last quarter?

Elicera Therapeutics AB released its earnings results on Apr 21, 2026. The company reported -kr0.102 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.102.

Is Elicera Therapeutics AB overvalued?

According to Wall Street analysts Elicera Therapeutics AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Elicera Therapeutics AB pay dividends?

Elicera Therapeutics AB does not currently pay dividends.

What is Elicera Therapeutics AB’s EPS estimate?

Elicera Therapeutics AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Elicera Therapeutics AB have?

Elicera Therapeutics AB has 72,803,314 shares outstanding.

What happened to Elicera Therapeutics AB’s price movement after its last earnings report?

Elicera Therapeutics AB reported an EPS of -kr0.102 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -32.414%.

Which hedge fund is a major shareholder of Elicera Therapeutics AB?

Currently, no hedge funds are holding shares in SE:ELIC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.